ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc. (ONCY)
Filing Type: Form 10-Q
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent designed to activate the immune system and sensitize tumors to other treatments. The company focuses on gastrointestinal cancers, including metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the anal canal (SCAC).
Corporate Status: The company completed a domestication from Canada to the State of Nevada on March 31, 2026, and changed its functional currency from the Canadian dollar to the U.S. dollar effective January 1, 2026.

Key Financial Metrics

Debt and Liquidity: The company has no traditional debt. Liabilities consist primarily of accounts payable, accrued liabilities, operating lease liabilities, and a stock option liability of $3,393 (reclassified from equity due to the functional currency change). As of June 30, 2026, the company held $4,115 in cash and cash equivalents.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss for the six months ended June 30, 2026, was $18.7 million, compared to $10.0 million in the prior year period. This increase is driven by higher operating expenses.
• Operating Expenses: Total operating expenses rose to $18.7 million from $9.7 million year-over-year.
  • R&D Expenses: Increased to $8.8 million from $4.7 million, primarily due to start-up costs for the Phase 2 second-line mCRC study (REO 033) and increased personnel-related expenses (including stock-based compensation).
  • G&A Expenses: Increased to $9.8 million from $5.0 million, driven by higher public company-related expenses (legal, tax, audit fees related to domestication) and increased personnel costs.
• Stock-Based Compensation: Total stock-based compensation expense was $5.5 million for the six months ended June 30, 2026, compared to $1.2 million in the prior year. This includes a significant reclassification of certain stock options from equity to liability due to the change in functional currency.
• Financing Activity: The company raised $14.4 million in net proceeds from At-The-Market (ATM) offerings during the six months ended June 30, 2026, compared to $8.3 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: The company has raised substantial doubt about its ability to continue as a going concern. Management states that existing cash resources ($4.1 million) are sufficient for near-term milestones but are not sufficient to fund planned operations for at least twelve months from the date of the report. Continued operations depend on obtaining additional financing.
• Clinical Outlook:
  • mCRC: Received Fast Track Designation for pelareorep in combination with FOLFIRI/bevacizumab. Launched the randomized Phase 2 REO 033 study in March 2026.
  • SCAC: Received Fast Track Designation in July 2026 for pelareorep in combination with a checkpoint inhibitor. Finalizing a pivotal study protocol with the FDA.
  • Preclinical: Initial data showed enhanced anti-tumor activity when combining pelareorep with RAS inhibitors.
• Capital Requirements: The company plans to raise additional capital through its ATM agreement with Jefferies LLC (up to $75 million aggregate offering price) and potential strategic collaborations. There is no assurance that financing will be available on acceptable terms.
• Unusual Items:
  • Functional Currency Change: Effective Jan 1, 2026, the functional currency changed to USD, resulting in the reclassification of certain stock options to liabilities and the reclassification of warrants to equity.
  • Domestication: Completed the move from Canada to Nevada, incurring significant one-time legal and professional fees reflected in G&A expenses.

Key Facts for Investor Verification

• Liquidity Runway: Verify the company's ability to secure additional funding, as current cash ($4.1M) is insufficient for a 12-month operating horizon.
• ATM Utilization: Monitor the pace of share sales under the Jefferies ATM agreement, which is the primary source of recent liquidity.
• Clinical Milestones: Track patient enrollment and data readouts for the REO 033 (mCRC) and the pivotal SCAC study, as these are critical for future valuation and partnership opportunities.
• Expense Trajectory: Assess if the significant increase in R&D and G&A expenses (driven by stock-based comp and domestication costs) is sustainable or if cost-cutting measures will be required.
• Contract Liability: Note the $4.9 million contract liability from the Adlai Nortye licensing agreement, which represents deferred revenue to be recognized over five years.